Femoston - instructions for use, reviews, analogs and formulations (tablets 1/5 mg Conti, 1/10 mg, 2/10 mg) drugs for the treatment of menopause and postmenopausal osteoporosis in women, including during pregnancy. Adverse effects of admission
In this article, you can read the instructions for using the drug Femoston. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors specialists on the use of Femoston in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Femoston in the presence of existing structural analogues. Use for the treatment of menopause and prevention of postmenopausal osteoporosis in women,including during pregnancy and lactation. Side effects of taking the drug (bleeding, discharge).
Femoston - a combined two-phase preparation for hormonal replacement therapy, containing as an estrogen component micronized 17beta-estradiol and as a progestogen component of dydrogesterone. Both components are analogues of female sex hormones (estradiol and progesterone).
Estradiol replenishes the estrogen deficiency in the female body after the onset of menopause and provides effective relief of psychoemotional and vegetative climacteric symptoms such as hot flashes, increased sweating, sleep disorders, increased nervous excitability, dizziness, headache, involution of the skin and mucous membranes, especially the genitourinary system and irritation of the vaginal mucosa, soreness in sexual intercourse).
Hormone replacement therapy (HRT) with Femoston prevents the loss of bone mass in the postmenopausal period, caused by estrogen deficiency.
Reception of the drug Femoston leads to a change in the lipid profile in the direction of lowering the level of total cholesterol and LDL and increasing HDL.
Dydrogesterone is an effective oral progestogen that completely ensures the onset of the secretion phase in the endometrium, thereby decreasing the risk of developing endometrial hyperplasia and / or carcinogenesis (increasing with the use of estrogens). Dydrogesterone does not possess estrogenic, androgenic, anabolic or glucocorticoid activity.
Composition
Estradiol + Dydrogesterone + auxiliary substances.
Estradiol hemihydrate + Dydrogesterone + excipients (Femoston Conti).
Pharmacokinetics
Estradiol
After taking the drug inside, micronized estradiol is easily absorbed. Estradiol is metabolized in the liver with the formation of estrone and estrone sulfate. Estrone sulfate is subjected to intrahepatic metabolism. Glucuronides of estrone and estradiol are excreted mainly in urine.
Dydrogesterone
In the human body, dydrogesterone is rapidly absorbed from the digestive tract. Metabolized completely. The main metabolite of dydrogesterone is 20-dihydrodidrogesterone, which is present in the urine mainly in the form of glucuronic acid conjugate.Complete elimination of dydrogesterone occurs after 72 hours.
Indications
- hormone replacement therapy due to natural menopause, or menopause caused by surgery;
- prevention of postmenopausal osteoporosis.
Forms of release
The tablets covered with a cover 1/5 mg (Conti), 1/10 mg, 2/10 mg.
Instructions for use and reception scheme
Femoston 1/5 Conti
The drug is taken orally daily, in continuous mode, 1 tablet per day (preferably at the same time of day), regardless of food intake.
Patients making a transition from another continuous sequential or cyclic regimen should complete the current cycle, and then switch to the Femoston Continent. Patients making the transition from a continuous combination regimen can start taking Femoston with a continuum on any given day.
If the patient missed the pill, it should be taken within 12 hours after the usual time of admission; otherwise, the missed tablet should not be taken, and the next day it is necessary to take the pill at the usual time.Skipping the drug may increase the likelihood of "breakthrough" uterine bleeding.
Femoston 1/10
Take 1 tablet a day (preferably at the same time of day) without interruption, regardless of food intake.
In the first 14 days of the 28-day cycle, 1 tablet of white color (from the half of the package with the arrow labeled "1") containing 1 mg of estradiol is taken daily, and in the remaining 14 days - 1 tablet of gray color with an arrow marked with the number "2") containing 1 mg of estradiol and 10 mg of dydrogesterone.
Femoston 2/10
Take 1 tablet a day (preferably at the same time of day) without interruption, regardless of food intake.
In the first 14 days of the 28-day cycle, 1 tablet of pink color is taken daily (from the half of the package with the arrow marked with the number "1") containing 2 mg of estradiol, and for the remaining 14 days - 1 tablet of light yellow color half of the package with an arrow marked with the number "2") containing 2 mg of estradiol and 10 mg of dydrogesterone.
Patients who have not stopped menstruating, are recommended to begin treatment on the first day of the menstrual cycle.Patients with irregular menstrual cycles are advisable to begin treatment after 10-14 days of monotherapy with progestogen ("chemical curettage").
Patients who have had their last menstrual period more than 1 year ago can start treatment at any time.
Side effect
- tenderness of the mammary glands;
- breakthrough bleeding;
- pelvic pain;
- changes in cervical erosion;
- change in secretion;
- dysmenorrhea;
- increased mammary glands;
- premenstrual like syndrome;
- change in libido;
- nausea, vomiting;
- flatulence;
- abdominal pain;
- pain in the back (waist);
- headache;
- migraine;
- dizziness;
- nervousness;
- depression;
- chorea;
- venous thromboembolism;
- myocardial infarction;
- hemolytic anemia;
- rash;
- itching;
- Chloasma;
- melasma;
- erythema multiforme;
- erythema nodosum;
- hemorrhagic purpura;
- hives;
- angioedema;
- change in body weight;
- vaginal candidiasis;
- breast carcinoma;
- increase in the size of the leiomyoma;
- peripheral edema;
- intolerance to contact lenses;
- exacerbation of porphyria.
Contraindications
- established or suspected pregnancy;
- lactation period (breastfeeding);
- diagnosed or suspected breast cancer, history of breast cancer;
- diagnosed or suspected estrogen-dependent malignant neoplasms;
- untreated endometrial hyperplasia;
- vaginal bleeding of unclear etiology;
- previous idiopathic or confirmed venous thromboembolism (deep vein thrombosis, pulmonary thromboembolism);
- active or recently transferred arterial thromboembolism;
- acute liver disease, as well as liver disease in the history (before the normalization of laboratory indicators of liver function);
- porphyria;
- hypersensitivity to the components of the drug.
Application in pregnancy and lactation
Femoston is contraindicated in pregnancy and lactation.
special instructions
Before the appointment or resumption of hormone replacement therapy, it is necessary to collect a complete medical and family history, conduct a general and gynecological examination to identify possible contraindications and conditions requiring compliance with precautionary measures.During treatment with the drug Femoston, it is recommended to conduct a periodic examination (the frequency and nature of the studies are determined individually). In addition, it is advisable to carry out a study of the mammary glands (including mammograms) in accordance with accepted norms, taking into account clinical indications.
The risk factors for thrombosis and thromboembolism with HRT are thromboembolic complications in history, severe forms of obesity (body mass index more than 30 kg / m2) and systemic lupus erythematosus. Regarding the role of varicose veins in the development of thromboembolism, there is no generally accepted opinion.
The risk of developing deep vein thrombosis of the lower extremities may temporarily increase with prolonged immobilization, extensive injuries or surgical interventions. In cases where prolonged immobilization is necessary after surgical interventions, consideration should be given to the temporary discontinuation of HRT 4 to 6 weeks before surgery.
When deciding HRT in patients with recurrent deep vein thrombosis or thromboembolism treated with anticoagulants, the use and risk of HRT must be carefully evaluated.
If thrombosis develops after the onset of HRT, the drug Femoston should be discontinued.
The patient should be informed of the need to consult a doctor if the following symptoms appear: painful swelling of the lower extremities, sudden loss of consciousness, dyspnea, visual impairment.
After consultation with the doctor, the patient should stop taking the medication if there is jaundice or worsening liver function, pronounced lifting of blood pressure, first detected migraine-like attack, pregnancy, manifestation of any contraindication.
There are data from studies showing a slight increase in the incidence of breast cancer in women who received HRT for a long time (more than 10 years). The probability of diagnosing breast cancer increases with the duration of treatment and returns to normal 5 years after discontinuation of HRT.
Patients who had previously received HRT using only estrogen preparations should be carefully examined before starting treatment with Femoston to identify possible hyperstimulation of the endometrium.
Breakthrough uterine bleeding and mildly expressed menstrual bleeding can occur during the first months of treatment with the drug.If, in spite of dose adjustment, such bleeding does not stop, the drug should be discontinued until the cause of bleeding is established. If bleeding recurs after a period of amenorrhea or continues after withdrawal of treatment, its etiology should be established. This may require an endometrial biopsy.
The drug Femoston is not a contraceptive. Patients in the perimenopause are recommended to use non-hormonal contraceptives.
The patient should inform the doctor about the medications that she is currently taking or taking before the appointment of the drug Femoston.
The use of estrogens can affect the results of the following laboratory tests: the determination of glucose tolerance, the study of the functions of the thyroid and liver.
Impact on the ability to drive vehicles and manage mechanisms
Femoston does not affect the ability to drive vehicles and drive mechanisms.
Drug Interactions
Simultaneous use of drugs that are inducers of microsomal liver enzymes (incl.barbiturates, phenytoin, rifampicin, rifabutin, carbamazepine), can weaken the estrogenic effect of the drug Femoston.
Ritonavir and nelfinavir, although known as inhibitors of microsomal metabolism, can play the role of inducers with simultaneous administration with steroid hormones.
Herbal preparations containing St. John's wort can stimulate the exchange of estrogens and progestogens.
The interaction of dydrogesterone, which is part of the drug Femoston, with other drugs is not known.
Analogues of the drug Femoston
Femoston does not have structural analogs for the active substance.
Analogues on the therapeutic effect (menopause and climacteric condition in women):
- Angelique;
- Artemis;
- Gynodian Depot;
- Hormoplex;
- Derremiril;
- Divertrain;
- Duphaston;
- Female beginning (Demeter);
- St. John's Wort;
- The individual;
- Inoklim;
- Climadinone;
- Climadinon Uno;
- Climaxan is homeopathic;
- Climakt-Hel;
- Climacoplane;
- Climara;
- Klimen;
- Klimodien;
- Cliogest;
- Microfolline;
- Ovariamine;
- Ovestin;
- Pausogest;
- Premarin;
- Proginova;
- Remens;
- Sinestrol;
- Triaclim;
- Trisequence;
- Cyclo-Proginova;
- Estimax;
- Estroel;
- Estrogele;
- Estrofem.
Similar medicines:
Other medicines:
- Ursosan - instructions for use, reviews, analogs and formulations (capsules or tablets 250 mg) of the drug for the treatment of hepatitis, jaundice and other liver diseases in adults, children (including newborns) and pregnancy
- Longitude - instructions for use, analogs, testimonials and release forms (candles 3000 IU, injections in ampoules for injection 1500 IU and 3000 IU) of a drug for the treatment of adhesions, contractures and scars in adults, children and in pregnancy
- Prestarium - instructions for use, analogs, reviews and release forms (tablets 2.5 mg, 5 mg, 10 mg A with arginine) drugs for the treatment of hypertension and heart failure in adults, children and in pregnancy